Combined FISH, IHC identifies patients with rare ALK Fusions that respond to crizotinib

The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment.
Source: ScienceDaily Headlines - Category: Science Source Type: news